Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain [PDF]
BMC Infectious Diseases, 2017 Background This study aimed at estimating the efficiency of palivizumab in the prevention of Respiratory Syncytial Virus (RSV) infection and its sequelae in preterm infants (32day 1-35day 0weeks of gestational age –wGA-) in Spain. Methods A decision-tree
M. Sanchez-Luna +6 more
doaj +2 more sources
Health Technology Assessment, 2008 Objectives: To systematically review the effectiveness and cost-effectiveness of palivizumab for the prevention of respiratory syncytial virus (RSV) in children and examine prognostic factors to determine whether subgroups can be identified with ...
D Wang +4 more
doaj +2 more sources
Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection [PDF]
Scientific Reports, 2021 Respiratory syncytial virus (RSV) infection is a common cause of hospitalisation in infants and the elderly. Palivizumab prophylaxis is the only approved treatment modality but is costly and only offered to select vulnerable populations.
Agata Antepowicz +5 more
doaj +2 more sources
Palivizumab and RSV prevention [PDF]
Archives of Disease in Childhood, 2000 Editor,—The letters from Drs Deshpande and Nicholl, in relation to the Impact-RSV study and the UK guidance for the use of palivizumab in the prevention of serious RSV infections, raise interesting questions that need to be addressed. I believe Dr Deshpande “has got it wrong” in that he fails to realise that the primary objective of the IMpact study ...
Warren Lenney
openaire +2 more sources
International Journal of Pediatrics (United Kingdom), 2014 Infection with respiratory syncytial virus (RSV) is one of the major causes globally of childhood respiratory morbidity and hospitalization. Palivizumab, a humanized monoclonal antibody, has been recommended for high risk infants to prevent severe RSV ...
Nusrat Homaira, Adam Jaffe
exaly +2 more sources
International Journal of General Medicine, 2018 Ahmad Abushahin, Ibrahim Janahi, Amjad Tuffaha Department of Pediatrics, Section of Pediatric Pulmonology, Hamad Medical Corporation, Doha, Qatar Objective: The primary objective of this study was to document the hospitalization rate due to ...
Abushahin A, Janahi I, Tuffaha A
doaj +3 more sources
Palivizumab‐Resistant Human Respiratory Syncytial Virus Infection in Infancy [PDF]
Clinical Infectious Diseases, 2010 Ortwin Adams +5 more
exaly +2 more sources
Adherence to Palivizumab for Respiratory Syncytial Virus Prophylaxis in Romanian Infants. [PDF]
Vaccines (Basel)Calomfirescu-Avramescu A +4 more
europepmc +3 more sources
Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen. [PDF]
PLoS ONE, 2017 Monthly injections of palivizumab during the respiratory syncytial virus (RSV) season in at-risk infants reduces RSV-associated hospitalizations. However, the additive effect of naturally acquired immunity remains unclear. The objective of this study was
Jennifer Claydon +9 more
doaj +1 more source
Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection
Viruses, 2023 (1) Background: Palivizumab has been an approved preventative monoclonal antibody for respiratory syncytial virus (RSV) infection for over two decades. However, due to its high cost and requirement for multiple intramuscular injections, its use has been ...
Hasindu S. Edirisinghe +10 more
doaj +1 more source